Personal information

Verified email addresses

Verified email domains

lung cancer, malignant pleural mesothelioma
Japan

Activities

Employment (4)

Shimane University Hospital: Izumo, JP

2024-06-01 to present | Vice Chair (Department of Thoracic Surgery)
Employment
Source: Self-asserted source
Hiromasa Yamamoto

Shimane University Hospital: Izumo, Shimane, JP

2024-01-01 to present | Professor & Director (Center for Clinical Genetics and Genomic Medicine)
Employment
Source: Self-asserted source
Hiromasa Yamamoto

Okayama University Hospital: Okayama, Okayama, JP

2021-12-01 to 2023-12-31 | Senior Assistant Professor (Department of Thoracic Surgery)
Employment
Source: Self-asserted source
Hiromasa Yamamoto

Okayama University Hospital: Okayama, Okayama, JP

2011-11-01 to 2021-11-30 | Assistant Professor (Department of Thoracic Surgery)
Employment
Source: Self-asserted source
Hiromasa Yamamoto

Education and qualifications (2)

Okayama Daigaku Daigakuin Ishiyakugaku Sogo Kenkyuka: Okayama, JP

2000-04-01 to 2005-03-31
Education
Source: Self-asserted source
Hiromasa Yamamoto

Okayama Daigaku - Shikata Campus: Okayama, JP

1994-04-01 to 2000-03-31
Education
Source: Self-asserted source
Hiromasa Yamamoto

Works (28)

Impact of C-Reactive Protein-to-Albumin Ratio on Lung Cancer With Interstitial Pneumonia

Annals of Thoracic Surgery Short Reports
2024-12 | Journal article
Contributors: Kei Matsubara; Hiromasa Yamamoto; Riki Okita; Shinji Otani; Mototsugu Watanabe; Tsuyoshi Ueno; Toshiharu Mitsuhashi; Takashi Tanaka; Takao Hiraki; Shinichi Toyooka
Source: check_circle
Crossref

Implication of S-1 biomarkers on aging and prognosis in elderly patients with lung cancer treated by adjuvant S-1 chemotherapy: Accompanying results of the Setouchi Lung Cancer Group Study 1201

2024-11-25 | Preprint
Contributors: Junichi Soh; Hiromasa Yamamoto; Norihito Okumura; Hiroyuki Suzuki; Masao Nakata; Toshiya Fujiwara; Kenichi Gemba; Isao Sano; Takuji Fujinaga; Masafumi Kataoka et al.
Source: check_circle
Crossref

Impact of the neutrophil-to-lymphocyte ratio on patients with locally advanced non-small cell lung cancer who suffer radiation pneumonitis during the course of induction chemoradiotherapy followed by surgery

Surgery Today
2024-09 | Journal article
Contributors: Yujiro Kubo; Hiromasa Yamamoto; Kei Matsubara; Kohei Hashimoto; Shin Tanaka; Kazuhiko Shien; Ken Suzawa; Kentaroh Miyoshi; Mikio Okazaki; Seiichiro Sugimoto et al.
Source: check_circle
Crossref

Adrenergic microenvironment driven by cancer‐associated Schwann cells contributes to chemoresistance in patients with lung cancer

Cancer Science
2024-07 | Journal article
Contributors: Yusuke Otani; Haruyoshi Katayama; Yidan Zhu; Rongsheng Huang; Takafumi Shigehira; Kazuhiko Shien; Ken Suzawa; Hiromasa Yamamoto; Tadahiko Shien; Shinichi Toyooka et al.
Source: check_circle
Crossref

ASO Visual Abstract: Prognostic Impact of Tumor-Infiltrating Lymphocytes, Tertiary Lymphoid Structures, and Neutrophil-to-Lymphocyte Ratio in Pulmonary Metastases from Uterine Leiomyosarcoma

Annals of Surgical Oncology
2023-12 | Journal article
Contributors: Naoki Matsuda; Hiromasa Yamamoto; Tomohiro Habu; Kazuma Iwata; Kei Matsubara; Shin Tanaka; Kohei Hashimoto; Kazuhiko Shien; Ken Suzawa; Kentaroh Miyoshi et al.
Source: check_circle
Crossref

Prognostic Impact of Tumor-Infiltrating Lymphocytes, Tertiary Lymphoid Structures, and Neutrophil-to-Lymphocyte Ratio in Pulmonary Metastases from Uterine Leiomyosarcoma

Annals of Surgical Oncology
2023-12 | Journal article
Contributors: Naoki Matsuda; Hiromasa Yamamoto; Tomohiro Habu; Kazuma Iwata; Kei Matsubara; Shin Tanaka; Kohei Hashimoto; Kazuhiko Shien; Ken Suzawa; Kentaroh Miyoshi et al.
Source: check_circle
Crossref

Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)—IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201

PLOS ONE
2023-05-19 | Journal article
Contributors: Hiromasa Yamamoto; Darren Wan-Teck Lim; Junichi Soh; Norihito Okumura; Hiroyuki Suzuki; Masao Nakata; Toshiya Fujiwara; Kenichi Gemba; Isao Sano; Takuji Fujinaga et al.
Source: check_circle
Crossref

Data from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Data from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Figure S1-S7 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Figure S1-S7 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Supplementary Figure legends from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Supplementary Figure legends from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Table S1 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Table S1 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

2023-04-03 | Preprint
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Functional Blockage of S100A8/A9 Ameliorates Ischemia–Reperfusion Injury in the Lung

Bioengineering
2022-11 | Journal article | Author
Contributors: Kentaro Nakata; Mikio Okazaki; Tomohisa Sakaue; Rie Kinoshita; Yuhei Komoda; Dai Shimizu; Haruchika Yamamoto; Shin Tanaka; Ken Suzawa; Kazuhiko Shien et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer‐associated fibroblast

Cancer Science
2022-10 | Journal article
Contributors: Kosuke Ochi; Ken Suzawa; Yin Min Thu; Fumiaki Takatsu; Shimpei Tsudaka; Yidan Zhu; Kentaro Nakata; Tatsuaki Takeda; Kazuhiko Shien; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Oncogenic potential of human pluripotent stem cell‐derived lung organoids with HER2 overexpression

International Journal of Cancer
2021-10-15 | Journal article
Contributors: Akihiro Miura; Daisuke Yamada; Masahiro Nakamura; Shuta Tomida; Dai Shimizu; Yan Jiang; Tomoka Takao; Hiromasa Yamamoto; Ken Suzawa; Kazuhiko Shien et al.
Source: check_circle
Crossref

A Simple Prognostic Benefit Scoring System for Sarcoma Patients with Pulmonary Metastases: Sarcoma Lung Metastasis Score

Annals of Surgical Oncology
2021-07-24 | Journal article
Contributors: Haruchika Yamamoto; Hiromasa Yamamoto; Junichi Soh; Etsuji Suzuki; Kei Namba; Ken Suzawa; Kentaroh Miyoshi; Shinji Otani; Mikio Okazaki; Seiichiro Sugimoto et al.
Source: check_circle
Crossref

A New Scoring System for Predicting the Survival of Sarcoma Patients with Pulmonary Metastases: Sarcoma Lung Metastasis Score

Annals of Surgical Oncology
2021-07-04 | Journal article
Contributors: Haruchika Yamamoto; Hiromasa Yamamoto; Shinichi Toyooka
Source: check_circle
Crossref

The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas

Surgery Today
2021-01-03 | Journal article
Contributors: Hiromasa Yamamoto; Kei Namba; Haruchika Yamamoto; Tomohiro Toji; Junichi Soh; Kazuhiko Shien; Ken Suzawa; Takeshi Kurosaki; Shinji Otani; Mikio Okazaki et al.
Source: check_circle
Crossref

YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers

Cancer Science
2020-03 | Journal article
Contributors: Tatsuaki Takeda; Hiromasa Yamamoto; Ken Suzawa; Shuta Tomida; Shunsaku Miyauchi; Kota Araki; Kentaro Nakata; Akihiro Miura; Kei Namba; Kazuhiko Shien et al.
Source: check_circle
Crossref

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells

Molecular Cancer Research
2019-02-01 | Journal article
Contributors: Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto et al.
Source: check_circle
Crossref

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer

Cancer Science
2018-10 | Journal article
Contributors: Hiroki Sato; Hiromasa Yamamoto; Masakiyo Sakaguchi; Kazuhiko Shien; Shuta Tomida; Tadahiko Shien; Hirokuni Ikeda; Minami Hatono; Hidejiro Torigoe; Kei Namba et al.
Source: check_circle
Crossref

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations

Cancer Science
2018-05 | Journal article
Contributors: Hidejiro Torigoe; Kazuhiko Shien; Tatsuaki Takeda; Takahiro Yoshioka; Kei Namba; Hiroki Sato; Ken Suzawa; Hiromasa Yamamoto; Junichi Soh; Masakiyo Sakaguchi et al.
Source: check_circle
Crossref

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer

Cancer Science
2018-04 | Journal article
Contributors: Takahiro Yoshioka; Kazuhiko Shien; Kei Namba; Hidejiro Torigoe; Hiroki Sato; Shuta Tomida; Hiromasa Yamamoto; Hiroaki Asano; Junichi Soh; Kazunori Tsukuda et al.
Source: check_circle
Crossref

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma

Oncogenesis
2018-01-24 | Journal article
Contributors: Hiroki Sato; Masakiyo Sakaguchi; Hiromasa Yamamoto; Shuta Tomida; Keisuke Aoe; Kazuhiko Shien; Takahiro Yoshioka; Kei Namba; Hidejiro Torigoe; Junichi Soh et al.
Source: check_circle
Crossref

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer

PLOS ONE
2017-02-03 | Journal article
Contributors: Tatsuaki Takeda; Ming Tan; Hiromasa Yamamoto; Hirotaka Kanzaki; Ken Suzawa; Takahiro Yoshioka; Shuta Tomida; Xiaojiang Cui; Ramachandran Murali; Kei Namba et al.
Source: check_circle
Crossref

Peer review (11 reviews for 3 publications/grants)

Review activity for General thoracic and cardiovascular surgery cases. (2)
Review activity for General thoracic and cardiovascular surgery. (8)
Review activity for PloS one. (1)